Table of Contents
The Competitive Intelligence Report Amyloid beta- and Tau-Targeted Antibodies & Vaccines as of September 2015 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease or progressive supranuclear palsy (PSP) by targeting amyloid-beta (beta-amyloid) or tau. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for amyloid beta- and tau-targeted passive and active imunotherapy of Alzheimer’s disease. In addition, the report lists company-specific R&D pipelines of amyloid beta- and tau-targeted antibodies & vaccines. Competitor projects are listed in a tabular format providing Information on:
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Get Industry Insights. Simply.
Talk to Amrita
+1 718 303 2019
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is ...